219 results
8-K
EX-99.1
INMB
INmune Bio Inc
30 Apr 24
Other Events
4:01pm
is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may … constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements
8-K
EX-99.2
INMB
INmune Bio Inc
30 Apr 24
Other Events
4:01pm
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do … not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any
8-K
EX-10.1
INMB
INmune Bio Inc
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
that this representation is made.
Litigation. Except as set forth on Schedule 3.1(j) or in the due diligence documentation provided to the Placement
8-K
EX-99.1
INMB
INmune Bio Inc
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical … facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking
424B5
1tf1n
26 Apr 24
Prospectus supplement for primary offering
4:26pm
8-K
EX-99.1
wxw2jgse42h
25 Apr 24
Other Events
4:35pm
8-K
EX-10.2
d0fej qa8o
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-99.1
ue9qj12m21aa7oq1sowe
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-10.1
pi4sj03j9quzpf59yyok
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
424B5
qvdy5gmzdmig5h2w
22 Apr 24
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
eewu23k4h 47lr7i1te
9 Apr 24
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4:58pm
8-K
EX-99.1
fny100 eu266zw
29 Mar 24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
4:01pm
8-K
EX-99.1
frlg99 pt
27 Mar 24
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
4:07pm
8-K
EX-99.1
qu819szanpe42
30 Jan 24
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
8:02am
8-K
EX-99.1
i26unw d78
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm
8-K
EX-99.1
0sl9wtxera37auec8sp
18 Dec 23
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
4:15pm
8-K
EX-99.1
4m1ea69ozu5tfv075 1f
29 Nov 23
Other Events
4:00pm
8-K
EX-99.1
xndxw v4yvs
27 Nov 23
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
4:00pm